Metraipolis › archive › dc_23137d9e8aab
Time-restricted eating in early-stage Huntington's disease: A 12-week interventional clinical trial protocol — Europe PMC PMID:40131943
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40131943
- DOI
- 10.1371/journal.pone.0319253
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T12:00:27.194Z
- SHA-256 of the archived text
c7ee597262f84c05ddb1652dc9976f491afa3e38f986152c12ca0052d74be2ab- Stable URL of this page
https://metraipolis.com/documento/dc_23137d9e8aab
How to cite
Time-restricted eating in early-stage Huntington's disease: A 12-week interventional clinical trial protocol — Europe PMC PMID:40131943 — Europe PMC (en), https://europepmc.org/article/MED/40131943 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_23137d9e8aab (Metraipolis archive dc_23137d9e8aab, sha256 c7ee597262f84c05ddb1652dc9976f491afa3e38f986152c12ca0052d74be2ab)
BibTeX
@misc{dc23137d9e8aab,
title = {Time-restricted eating in early-stage Huntington's disease: A 12-week interventional clinical trial protocol — Europe PMC PMID:40131943},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40131943},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_23137d9e8aab; sha256 c7ee597262f84c05ddb1652dc9976f491afa3e38f986152c12ca0052d74be2ab},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40131943. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by a variety of debilitating symptoms including abnormal motor control, cognitive impairment, and psychiatric disturbances. Despite significant efforts, efficacious treatments to alter the course of HD remain elusive, highlighting the need to explore new therapeutic strategies, including lifestyle changes that may delay the onset of symptoms and slow disease progression. Recent research indicates that time-restricted eating (TRE), a type of intermittent fasting where caloric intake is confined to a specific time window each day, may be beneficial in treating neurodegenerative diseases like HD. TRE has been found to enhance mitochondrial function, stimulate autophagy, lower oxidative stress, and improve cognitive performance. Although TRE has shown potential in HD animal models and non-HD populations, it has yet to be analyzed for safety, feasibility, and efficacy in persons with HD. Therefore, we propose a prospective interventional, open-label, single-arm, pilot study of 25 participants with late prodromal and early manifest HD to evaluate participant adherence to TRE diet - specifically, maintaining a 6-8-hour eating window every day for 12 weeks. Secondary measures will include pre- versus post-intervention assessment of body composition via bioelectrical impedance analysis, vital signs and safety labs, serum biomarkers of neurodegeneration, and standard HD behavioral, cognitive, and motor function clinical scales. Additional exploratory measures will evaluate sleep quality, physical activity, mood, dietary composition, and mitochondrial function. We expect that the diet will be safe, feasible, and may also improve biomarkers of disease progression in persons with HD. We anticipate this study will lay the foundation for future large-scale clinical trials to further evaluate the clinical efficacy of TRE in HD. This study has been registered on July 8, 2024 with ClinicalTrials.gov registration number NCT06490367 (https://clinicaltrials.gov/study/NCT06490367). Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-03-25). Identificativi: PMID 40131943 · PMCID PMC11936236 · DOI 10.1371/journal.pone.0319253. Descrittori MeSH principali: Huntington Disease; Fasting. Pagina: https://europepmc.org/article/MED/40131943 — https://doi.org/10.1371/journal.pone.0319253. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T10:21:18.014Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.